Some of the nations largest pharmaceutical companies have dramatically reduced payments to health professionals for promotional speeches amid heightened public scrutiny of such spending a ProPublica analysis shows Eli Lilly  Cos payments to speakers dropped by  percent from  million in  to  million in  Pfizers speaking payments fell  percent over the same period from nearly  million to  million And Novartis the largest drugmaker in the US as measured by  sales spent  percent less on speakers that year than it did between October  and September  reducing payments from  million to  million The sharp declines coincide with increased attention from regulators academic institutions and the public to pharmaceutical company marketing practices A number of companies have   in recent years that accused them of improperly marketing their drugs In addition the Physician Payment Sunshine Act a part of the  health reform law will soon require all pharmaceutical and medical device companies to   to physicians The first disclosures required under the act are expected in September and will cover the period of August to December  Within the industry some companies are reevaluating the role of physician speakers in their marketing repertoire GlaxoSmithKline   that it would stop paying doctors to speak on behalf of its drugs Its speaking tab plummeted from  million in  to  million in  Not all companies have cut speaker payments Johnson  Johnson increased such spending by  percent from  to  AstraZenecas payments stayed about flat in  after a steep decline the previous year ProPublica has been tracking publicly reported payments by drug companies since  as part of its   project Users can search for their doctors to see if they have received compensation from the  companies that make such information available online Weve just updated our application to include payments made through the end of  totaling  billion Forest Labs which only began reporting in  reported speaking payments of  million more than any other company in Dollars for Docs Some companies in the database said their declines have less to do with the Sunshine Act and more to do with the loss of patent protection for key products Lilly for example began facing generic competition to its blockbuster antipsychotic Zyprexa in late  Its antidepressant Cymbalta lost its patent at the end of  The value of educational programs tends to be higher when were launching a new medicine or we have new clinical datanew indication Lilly spokesman J Scott MacGregor said in an email adding that the drop in speaking payments also reflects the increased use of Web conferencing Pfizers patent on Lipitor its topselling cholesterol drug expired in  Like any other company our business practices must adapt to the changing nature of our product portfolio based in part on products going off patent and new products being introduced into the market company spokesman Dean Mastrojohn said in an email Novartis patent for its breast cancer drug Femara expired in  its hypertension drug Diovan in  and its cancer drug Zometa in  In a statement Novartis said speaking payments dropped in  in part because of a shift from big blockbuster drugs that many doctors prescribe toward specialty products prescribed by fewer physicians Resources were also shifted to support potential future product launches a spokeswoman said in an email The industrys increased emphasis on expensive specialty medications for such conditions as multiple sclerosis or hepatitis C has been striking said Aaron Kesselheim an assistant professor of medicine at Harvard Medical School A piece in the   last week noted that   approved by the Food and Drug Administration since  were for rare diseases and cancers Its possible the number of physicians they need to support sales of these items is less leading to lower payments overall Kesselheim said In some cases companies maintained or made smaller cuts to other forms of physician compensation while pulling back dramatically on speaking payments Pfizers spending on consultants dropped  percent from  to  far less than its payments to speakers The companys spending on research stayed essentially the same Lilly increased spending on physician researchers by more than  percent while reducing payments to consultants by more than twothirds Many bioethicists and leaders of major academic medical centers frown upon physicians delivering promotional talks for drug companies saying they turn doctors into sales representatives rather than leaders in research and patient care Officials with Pharmaceutical Research and Manufacturers of America an industry trade group dispute this characterization They said they are working with their member companies to prepare for the Sunshine Act and have created a campaign to promote the value of drug companydoctor collaborations Companies will make their own independent decisions about how to engage professionals said Kendra Martello PhRMAs deputy vice president of strategic operations Scott Liebman an attorney who advises pharmaceutical companies on the Sunshine Act said its too early to know how much the laws requirements are affecting company practices in part because its so new The fact that some companies are cutting back on speaking while preserving their spending on research and consulting suggests that other business forces could be at play he added Its very hard to pinpoint exactly why thats happening Liebman said I think theres a lot of potential answers to that I just dont know which is the right one